|
Author:
|
Saaresranta, Tarja; Hedner, J.; Bonsignore, Maria R.; Riha, Renata L.; McNicholas, Walter T.; Penzel, Thomas; Anttalainen, Ulla; Kvamme, John Arthur; Pretl, Martin; Sliwinski, Pawel; Verbraecken, Johan; Grote, Ludger
|
|
Notes:
|
Background: Clinical presentation phenotypes of obstructive sleep apnoea (OSA) and their association with comorbidity as well as impact on adherence to continuous positive airway pressure (CPAP) treatment have not been established.
Methods: A prospective follow-up cohort of adult patients with OSA (apnoea-hypopnoea index (AHI) of ≥5/h) from 17 European countries and Israel (n = 6,555) was divided into four clinical presentation phenotypes based on daytime symptoms labelled as excessive daytime sleepiness (“EDS”) and nocturnal sleep problems other than OSA (labelled as “insomnia”): 1) EDS (daytime+/nighttime-), 2) EDS/insomnia (daytime+/nighttime+), 3) non-EDS/non-insomnia (daytime-/nighttime-), 4) and insomnia (daytime-/nighttime+) phenotype.
Results: The EDS phenotype comprised 20.7%, the non-EDS/non-insomnia type 25.8%, the EDS/insomnia type 23.7%, and the insomnia phenotype 29.8% of the entire cohort. Thus, clinical presentation phenotypes with insomnia symptoms were dominant with 53.5%, but only 5.6% had physician diagnosed insomnia. Cardiovascular comorbidity was less prevalent in the EDS and most common in the insomnia phenotype (48.9% vs. 56.8%, p<0.001) despite more severe OSA in the EDS group (AHI 35.0±25.5/h vs. 27.9±22.5/h, p<0.001, respectively). Psychiatric comorbidity was associated with insomnia like OSA phenotypes independent of age, gender and body mass index (HR 1.5 (1.188–1.905), p<0.001). The EDS phenotype tended to associate with higher CPAP usage (22.7 min/d, p = 0.069) when controlled for age, gender, BMI and sleep apnoea severity.
Conclusions: Phenotypes with insomnia symptoms comprised more than half of OSA patients and were more frequently linked with comorbidity than those with EDS, despite less severe OSA. CPAP usage was slightly higher in phenotypes with EDS.
The authors thank the European Sleep Research Society (ESRS) and the European Respiratory Society (ERS) for their nonfinancial support in terms of logistics for communication, meetings and data presentations. The ESADA is supported by a current Clinical Reseach Cooperation (CRC) grant. The authors acknowledge the financial support of Philips Respironics PLC and ResMed PLC, which each provided unrestricted grants to support overall maintenance of the European Sleep Apnea Database (ESADA) Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
